← Leaderboards
Andrew Griswold
Weill Medical Coll Of Cornell Univ
$193,070
Attributed
$193,070
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $51K · FY2019–22$100K$75K$50K$25K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$193,070 · 1
By mechanism
F30$193,070 · 1
Top collaborators
No co-investigators on record.
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Lawrence J Stern$29,557,910
- Matteo Porotto$18,361,086
- Laura Santambrogio$19,202,907
- Costantino Iadecola$45,312,269
- Steven Monroe Lipkin$27,661,021
Others in their field
Other Emerging Leaders on “Acute Myelocytic Leukemia”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,430,568
- Crystal Mackall · Children'S Hosp Of Philadelphia$6,450,142
- Christopher A Miller · Washington University$5,424,298
- Eric Padron · H. Lee Moffitt Cancer Ctr & Res Inst$5,329,699
- Kelly Diringer Getz · University Of Pennsylvania$4,068,250
Research focus
Acute Myelocytic LeukemiaAdultAnticancer ActivityAcute Myeloid Leukemia CellBiochemicalBiologicalBiotechnologyBiotinBenchmarkingCasp9 GeneCaspaseCell DeathCell LineCellsCellular AssayChemical GroupChemistryChemoproteomicsCancer InitiationComplexCouplingCrispr/Cas TechnologyCytokineCytotoxic
Grant awards (4)
Characterizing the DPP8/9 Pyroptotic Checkpoint with Chemoproteomic Protease Substrate Profiling$48,000
F30 · FY2022 · CA · contact PI
Characterizing the DPP8/9 Pyroptotic Checkpoint with Chemoproteomic Protease Substrate Profiling$51,036
F30 · FY2021 · CA · contact PI
Characterizing the DPP8/9 Pyroptotic Checkpoint with Chemoproteomic Protease Substrate Profiling$47,269
F30 · FY2020 · CA · contact PI
Characterizing the DPP8/9 Pyroptotic Checkpoint with Chemoproteomic Protease Substrate Profiling$46,765
F30 · FY2019 · CA · contact PI